Webinars & Online Seminars

What will be covered?

• Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
• Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
• Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells

What will be covered?

• 全てのヒトのターゲットで安全性を確認
• 通常の結合データを上回る機能データ
• アッセイ開発のコストと時間を削減

What will be covered?

• Overview of compound-target engagement
• Tools and workflow to create your own cell-based target engagement assay
• Applications of InCELL Pulse assays

What will be covered?

• Using phenotypic profiling to characterize clinically successful drugs for a given indication
• Combining target-based and phenotypic data to prioritize drugs for repurposing
• Understanding how multi-targeted kinases can be pivoted towards new indications

What will be covered?

• Role of GPCRs in human cardiovascular system
• Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
• Identifying biased agonists using pharmacologically-relevant functional cell based assays
• Validating assays and minimizing inter-assay variation

What will be covered?

• Overview of compound-target engagement and InCELL Pulse platform
• Kinase drug discovery importance
• Tools and workflow needed to create your own target engagement assay
• Validation data showing several examples of diverse kinases

What will be covered?

• 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
• 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系

What will be covered?

• Overview of the mu opioid receptor signaling
• GPCR splicing, using OPRM1 as an example
• Region and cell specific splicing
• Functional consequences of 5’ splicing
• Functional consequences of 3’ splicing

What will be covered?

• Opportunities and challenges for targeting GPCRs in oncology
• Examples of GPCR-targeting investigational therapies for oncology
• Imipridones, selective GPCR-targeting small molecules, that are in preclinical and clinical development for oncology

What will be covered?

• Learn about the significance of kinase broad profiling and phenotypic screening on early kinase drug discovery
• Learn how to design a kinase inhibitor broad profiling project and how the chemo-bioinformatic analysis can impact target deconvolution after phenotypic screening

What will be covered?

• Overview of compound-target engagement
• Tools needed to create your own target engagement assay
• Experimental design and workflow
• Applications of InCELL Pulse assays

What will be covered?

• Screening approaches for GPCR drug discovery
• Creating a duplexed assay to monitor calcium and β-arrestin in a single well

• Determine potential bias for various drugs and define potency ranking

What will be covered?

• Challenges in immuno-oncology drug development
• Tools to expedite and simplify any immuno-oncology drug development pipeline

What will be covered?

• Overview of the BioMAP® immuno-oncology/oncology systems
• Information BioMAP iOnc studies provide
• Host stromal/vascular - tumor microenvironment biology
• Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds

What will be covered?

• 2016の創薬市場：「スマート」になった現在の薬剤
• チェックポイント阻害剤の評価系・インターロイキン受容体・GPCR等
• キナーゼ阻害剤・エピジェネティック阻害剤・PPI創薬のスクリーニング
• 候補薬剤の表現型プロファイリング

What will be covered?

• Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
• Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
• Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications

What will be covered?

• How PathHunter^® GPCR Screening and Profiling Services can be used to triage hits, rank order compounds, and develop novel biased ligands
• Tools to understand the mechanism of action of your drugs and their mode of action
• How a case study of clinically approved drugs in our broad range of GPCR assays can be used to predict the selectivity and safety of your drug candidates

What will be covered?

• Overview of the KINOMEscan assay technology
• Application of the KINOMEscan platform for selectivity and potency optimization
• Development of chemical probes for understudied kinases

What will be covered?

• Novel cell-based assays for checkpoint signaling receptors
• Functional assays for biologics and small molecule screening
• Applications for QC lot release testing of biologics
• Assays for CD137, CTLA-4, TIGIT, PD-1, OX-40, CD40, TWEAK, TIM3, and VISTA
• Custom assay development for novel checkpoint targets

What will be covered?

• KINOMEscanアッセイ原理の詳細：結合系と機能系を比較
• 新規キナーゼ標的：CDK10, CDK12, CDK20, MLKL and MLKL (full length), IRAK2 等
• 40種類ものブロモドメインに対する阻害剤を評価
• アポトーシス阻害剤の同定：BCL2scan
• scanMAX報告書から得られる、裏データ・裏情報のご紹介

What will be covered?

• Overview of β-arrestin biology
• Tools needed to create your own β-arrestin cell lines and assays
• Experimental design and workflows
• Applications of β-arrestin cell-based assays for GPCRs

What will be covered?

• Simple cell-based assays to measure target cell cytotoxicity in a co-culture
• Assays for ADCC, ADCP, bi-specific antibody mediated T-cell redirection, and adoptive T-cell therapies such as CAR-T
• Enabling technology to drive a cancer immunotherapy drug through the discovery and development pipeline

What will be covered?

• How to maximize knowledge of your compounds using the BioMAP^® Diversity PLUS™ panel of human primary cells systems
• How to understand mechanism classification analysis and toxicity signatures
• A case study on discovery of a mechanism-based novel signature for skin irritation

What will be covered?

• Creation of cell-based bioassays for potency and stability testing
• Application, development and validation of assays with drug molecule
• Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
• Qualified assays for > 30 biosimilars

What will be covered?

• Capabilities overview of LeadHunter Discovery Services
• Identifying, characterizing and quantifying novel biased ligands using LeadHunter Services

• Multiple pathways including ß-Arrestin and how biased signaling can influence efficacy in vivo

What will be covered?

• Tofacitinibの様な抗炎症剤から、食材までの表現型解析例の紹介
• 臨床試験への架け橋となったデータの実施例
• Skin Rash・Thrombosis等を明瞭に：BioMAPシステムの応用例
• パワーアップした試験報告書のご紹介：さらに充実したデータのご提供
• メカニズム探査によるリード化合物の毒性、薬理、安全性等の同定

What will be covered?

• Overview of membrane protein trafficking and protein misfolding diseases
• Assay technology to simplify monitoring of protein trafficking
• Screening for pharmacological chaperones

What will be covered?

• Simple cell-based assays for checkpoint signaling receptors
• Assays with human primary cells in co-culture recreating the human tumor microenvironment

• Enabling technologies to move an immune-oncology drug along the discovery and development pipeline
• Drugs targeting PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others

What will be covered?

• 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA　などの実施例
• 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系

What will be covered?

• Application of KINOMEscan technology for selectivity and potency optimization of your lead molecules
• Design scanMAX, KdELECT or scanELECT experiments
• Improved flexibility of custom panels for hit identification, hit to lead, SAR and lead optimization
• 20 new kinase assays launched in 2016

What will be covered?

• Novel cell-based assays for checkpoint signaling receptors
• PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
• Functional assays for biologics and small molecule screening
• Applications for QC lot release testing of biologics

What will be covered

• How BioMAP systems creates a unique profile for your drug
• Case studies using the screening technology platform
• Applications for phenotypic drug discovery
• Services offered for compound profiling

eSeminarの課題:

• Gi Tox、Skin Rash等の応用実施例の紹介
• リード化合物の選択や臨床標準治療との直接比較
• メカニズム探査によるリード化合物の毒性、薬理、安全性等の同定
• 2016年度パネルスケジュール

What will be covered

• Overview of the KINOMEscan technology
• Analysis of the KINOMEscan study report and included data information
• Application of the KINOMEscan platform for Selectivity and Potency optimization
• Data visualization tool: TREEspot™

What will be covered

• Capabilities overview of LeadHunter Discovery Services
• How LeadHunter can be used to identify, characterize and quantify novel biased ligands
• Discover how multiple pathways including ß-Arrestin can influence efficacy in vivo

eSeminarの課題:

• ADCC活性（Antibody-Dependent-Cellular-Cytotoxicity：抗体依存性細胞傷害）の評価系
• インターロイキン受容体のセルベースアッセイ
• BioMAP: MicroArray、FACS、下流タンパク質のリン酸化状態の追加サービス

What will be covered

• Basics of Enzyme Fragment Complementation (EFC)
• Application of EFC in protein-protein interaction, protein movement and protein quantification study in a cell-based setting
• Assays built to cover GPCRs, Receptor Tyrosine Kinases, Signaling Pathways and Epigenetics Targets

What will be covered?

• Creation of functional cell-based assays for interleukins and their receptors
• Application, development and validation of assays
• Validated functional assays for >80% of interleukins spanning every family
• Use of these assays for Screening, QC lot release and NAb applications

What will be covered

• Overview of target engagement assays
• Introduction to InCELL Hunter assays
• Explore applications for kinase, epigenetic or other protein targets

What will be covered

• Overview of the BioMAP Immuno-Oncology/Oncology Systems
  • Host Stromal/Vascular - Tumor Microenvironment Biology
  • Inflammation/Immune Biology
  • Comparison to MLR (Mixed Lymphocyte Reaction) assays
  • Immunophenotypic analysis
• Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds
• Case studies of combination studiest

What will be covered

• How BioMAP systems creates a unique profile for your drug
• Case studies using the screening technology platform
• Applications for phenotypic drug discovery
• Services offered for compound profiling

What will be covered

• Overview of the BioMAP Fibrosis Systems
• Case studies of IPF drugs, their combination and other fibrosis related compounds using the screening technology platform
• Applications for phenotypic drug discovery and compound profiling

eSeminarの課題:

• インターロイキンのセルベースアッセイのご紹介
• アッセイ系の応用、開発そしてバリデーションの解説
• インターロイキン・ファミリーを80%以上網羅する幅広いメニュー

What will be covered

• Overview of the KINOMEscan technology platform
• Explanation of the data included in the KINOMEscan study report
• Designing efficient strategies for KINOMEscan screening
• Data analysis overview: frequently overlooked data provided by scanMAX® screens
• An introduction to a useful data visualization tool: TREEspot™

What will be covered

• Creation of functional cell-based assays for interleukins and their receptors
• Application, development and validation of assays
• Validated assays for >80% of interleukins spanning every family
• Use of these assays for Screening, QC lot release and NAb applications

What will be covered?

• Overview of our novel enzyme fragment complementation technology
• Introduction to the assay principle
• Explore several applications for basic research and drug discovery (performing molecular profiling and identifying allosteric modulators, partial agonists, neutralizing Abs and more)

What will be covered

• Creation of functional cell-based assays for interleukins and their receptors
• Application, development and validation of assays
• Validated assays for >80% of interleukins spanning every family
• Use of these assays for Screening, QC lot release and NAb applications

What will be covered

• Capabilities overview of LeadHunter Discovery Services
• How LeadHunter can be used to identify and characterize novel biased ligands
• Discover how multiple pathways including ß-Arrestin can influence efficacy in vivo

What will be covered?

• Creation of cell-based bioassays for potency and stability testing
• Application, development & validation of assays
• Validated assays for >30 Biosimilars, RTKs, GPCRs, Interleukins, TGF-beta superfamily & Cytokine receptors
• Case studies on Avastin and Erythropoietin

What will be covered?

• 酶片段互补技术的概述
• 检测原理介绍
• 探讨本方法在基础研究及新药研发中的一些应用（展示分子特性及鉴定变构调节剂，部分激动剂，中和抗体等）

eSeminarの課題:

• BioMAPスクリーニング技術の概要
• BioMAP 線維症システム、オンコロジーシステム及びコンビネーション評価システムのご紹介
• ケーススタディ [免疫チェックポイント阻害剤のスクリーニング]
• フェノタイプ創薬と化合物プロファイリングへの適用

What will be covered?

• Overview of BioMAP® Technology Platform
• Case studies and applications of phenotypic screening in drug discovery
• Services offered for compound profiling

What will be covered?

• Technology for creation of cell based assays
• Application, development & qualification for Potency & NAb assays
• Use of frozen ready to assay cells for bioassay purpose
• Case studies on bioassays for Bevacizumab, Insulin, Epo, Ustekinumab, GLP receptor agonists, among others
• Available Bioassays for over 30 biosimilars

What will be covered?

• Overview of our novel enzyme fragment complementation technology
• Introduction to the assay principle
• Explore several applications for basic research and drug discovery (performing molecular profiling and identifying allosteric modulators, partial agonists, neutralizing Abs and more)

What will be covered?

• Introduction to the BioMAP Technology Platform
• Discussion of the challenges of building high throughput, physiologically relevant assays
• Description of methods for analysis of large, phenotypic assay data sets
• Case study:  the discovery of a novel mechanism underlying thrombosis-related side effects

What will be covered?

• Overview of the BioMAP systems
• Case studies using the screening technology platform
• Applications for phenotypic drug discovery
• Services offered for compound profiling

What will be covered

• Capabilities overview of LeadHunter Discovery Services
• Explore how LeadHunter can be used to triage hits, rank order compounds and develop novel biased ligands
• Discover how multiple pathways including ß-Arrestin can influence efficacy in vivo

What will be covered?

• Technology for creation of novel cell based assays
• Application, development & validation of NAb assays
• Applications to various targets, including GPCRs RTKs & Cytokine receptors
• Case studies on GPCR & Cytokine Receptor target

What will be covered?

• Creation of cell-based bioassays for potency and stability testing
• Application, development & validation of assays
• Validated assays for >30 Biosimilars, RTKs, GPCRs, Interleukins, TGF-beta superfamily & Cytokine receptors
• Case studies on Avastin and Erythropoietin

eSeminarの課題：

• 納品物である、試験報告書の詳細
• KINOMEscanアッセイ原理の詳細
• データ解析法の紹介
• scanMAX報告書から得られる、裏データ・裏情報

What will be covered?

• Overview of the KINOMEscan assay technology
• Experimental design:  strategies for choosing a screening concentration
• Interpretation of screening data: what to study and what to ignore
• Predicting inhibitor affinities from single point screening data
• Efficient strategies for designing follow-up experiments
• Selectivity is in the eye of the beholder: data visualization using TREEspot™ and Scatter Plots

What will be covered

• Technology for creation of novel cell based assays
• Application, development & validation of assays
• Applications to various targets, including RTKs, TGF-beta superfamily & Cytokine receptors
• Case studies on Cytokine Receptor & RTK targets

What will be covered

• Overview of the BioMAP Oncology Systems
• Case studies of immune check point antibodies using the screening technology platform
• Applications for phenotypic drug discovery and compound profiling

What will be covered

• Overview of protein trafficking and protein misfolding diseases
• Description of our novel enzyme fragment complementation technology to monitor trafficking of proteins
• Assay validation (ADRB2)
• Case studies (CFTR and more)

What will be covered

• Overview of the BioMAP Oncology Systems
• Case studies of immune check point antibodies using the screening technology platform
• Applications for phenotypic drug discovery and compound profiling

What will be covered

• Technology for creation of novel cell based assays
• Application, development & validation of assays
• Applications to various targets, including RTKs, TGF-beta superfamily & Cytokine receptors
• Case studies on Cytokine Receptor & RTK targets

What will be covered?

• Overview of protein trafficking and protein misfolding diseases
• Description of our novel enzyme fragment complementation technology to monitor trafficking of proteins
• Assay validation (ADRB2)
• Case studies (CFTR and more)

What will be covered?

What will be covered?

eSeminarの課題：

What is covered

What will be covered?

eSeminarの課題：

What is Covered

• Understand the InCELL Hunter technology platform
• Learn how to develop your own intracellular binding assays for methyltransferase, bromodomain and kinase proteins
• Explore case studies for target engagement of ATP-competitive and allosteric kinase inhibitors

What will be covered?

What will be covered?

• Understand the InCELL Hunter technology platform
• Learn how to develop your own intracellular binding assays for methyltransferase, bromodomain and kinase proteins
• Explore case studies for target engagement of ATP-competitive and allosteric kinase inhibitors

What will be covered?

• Overview of the KINOMEscan assay technology
• Analysis of the KINOMEscan study report and included data information
• Refresher on efficient strategies for designing KINOMEscan experiments
• Data analysis overview:  frequently overlooked data provided by scanMAX screens
• Data visualization tools: TREEspot

What will be covered?

What will be covered?

内容包括

• 如何将Arrestin技术和其他GPCR筛选技术结合以进行初期筛选结果验证，
• 化合物作用机理研究，
• 化合物副作用研究，
• 大分子药物和生物标记检测等。
• 还有关于孤儿受体GPCR的个案研究。

What will be covered?

What will be covered?

• 如何将Arrestin技术和其他GPCR筛选技术结合以进行初期筛选结果验证
• 化合物作用机理研究
• 化合物副作用研究
• 大分子药物和生物标记检测
• 关于孤儿受体GPCR的个案研究

What will be covered?

What will be covered?

What will be covered?

• KINOMEscan 技术综述
• 激酶抑制剂同激酶结合状态的重要性和基于活化状态的激酶抑制剂结合
• 激酶抑制剂结合和脱离的动力学
• 70个已知蛋白激酶抑制剂在Kinome水平的特异性分布：我们从中可以了解什么?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

• Overview of the KINOMEscan assay technology
• Experimental design:  strategies for choosing a screening concentration
• Interpretation of screening data: what to study and what to ignore
• Predicting inhibitor affinities from single point screening data
• Efficient strategies for designing follow-up experiments
• Selectivity is in the eye of the beholder: data visualization using TREEspot™ and Scatter Plots

What will be covered?

What will be covered?

• Overview of the BioMAP systems
• Case studies using the screening technology platform
• Applications for phenotypic drug discovery
• Services offered for compound profiling

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

What will be covered?

• Overview of the BROMOscan℠ technology platform
• Inhibitor binding assays for the BET family and other diverse bromodomain targets
• Assay validation strategies
• Application to HTS, selectivity profiling and quantitative affinity (Kd) determinations